Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Biometric Identity and Authentication Provider BIO-key to host Q1'26 Investor Webcast Monday, May 18th at 10am ET
07:59am, Tuesday, 12'th May 2026
HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host
Bio-Rad to Participate in Upcoming Investor Conferences
09:00am, Friday, 08'th May 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will p
Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
10:16am, Monday, 04'th May 2026
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Bio-Rad Laboratories Inc (BIO) Stock Down 8.4% -- Now Undervalued? GF Score: 77/100
05:29pm, Friday, 01'st May 2026
On May 01, 2026, Bio-Rad Laboratories Inc (BIO) shares fell 8.4% today, bringing the current price to $256.55. This decline is significant in the context of the
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
06:01am, Friday, 01'st May 2026
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates
07:26pm, Thursday, 30'th Apr 2026
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $1.89 per share, missing the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.54 per share a year ago.
Bio-Rad Reports First-Quarter 2026 Financial Results
04:15pm, Thursday, 30'th Apr 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
08:01am, Tuesday, 28'th Apr 2026
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- V
Following Stockholder Approval, BIO-key Announces 1-for-10 Reverse Stock Split
07:59am, Tuesday, 28'th Apr 2026
HOLMDEL, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, toda
Boston Trust Walden Corp Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
05:08am, Thursday, 23'rd Apr 2026
Boston Trust Walden Corp decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and E
BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing
04:45pm, Wednesday, 22'nd Apr 2026
HOLMDEL, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, annou
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
04:15pm, Thursday, 16'th Apr 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
Longleaf Partners Global Fund Q1 2026 Portfolio Review
02:30pm, Thursday, 16'th Apr 2026
During the quarter Longleaf Partners Global Fund had no new purchases and exited four holdings: Bio-Rad, Louis Hachette, Louisiana-Pacific and Walt Disney. Glanbia's shares held up well in a difficult
Analyzing Bio-Rad Laboratories (NYSE:BIO) & Haemonetics (NYSE:HAE)
02:26am, Wednesday, 15'th Apr 2026
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two business
